Algerian heart patients monitored on common blood thinner
NCT ID NCT06184204
Summary
This study observed nearly 400 Algerian adults with atrial fibrillation who were prescribed the blood thinner Trombix® (rivaroxaban). The goal was to see how safe and effective the drug is in everyday use and how it affects patients' quality of life. Researchers tracked side effects like serious bleeding, strokes, and reasons patients might stop taking the medication over a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AOUICHE private healthcare
Constantine, Algeria
-
Ali Lahmar private healthcare
Oran, Algeria
-
BEDAI private healthcare
Annaba, Algeria
-
Berboucha
Annaba, Algeria
-
Boudjelal private healthcare
Batna City, Algeria
-
Boumaaza Private healthcare
Algiers, Algeria
-
CHU Mustapha
Algiers, Algeria
-
CHU Oran
Oran, Algeria
-
EID private healthcare
Oran, Algeria
-
EPH Tipaza
Tipasa, Algeria
-
Fernane private healthcare
Tizi Ouzou, Algeria
-
HAMDI private healthcare
Constantine, Algeria
-
KHAITER Private healthcare
Blida, Algeria
-
Mouffok private healthcare
M'Sila, Algeria
-
NASSOUR private healthcare
Tlemcen, Algeria
-
OKBI Private healthcare
Biskra, Algeria
-
Sebbagh Private Healthcare
Sidi Bel Abbes, Algeria
Conditions
Explore the condition pages connected to this study.